8-K: Soleno Therapeutics Stockholders Re-Elect Directors and Ratify Auditor at 2025 Annual Meeting

Soleno Therapeutics, Inc. announced the successful re-election of two Class II directors and the ratification of its independent public accounting firm at its 2025 Annual Meeting of Stockholders, with a high quorum of 94.7%.

Summary

• Soleno Therapeutics, Inc. held its 2025 Annual Meeting of Stockholders on June 5, 2025.
• A significant quorum was achieved with 47,273,966 shares represented, constituting approximately 94.7% of the 49,908,303 shares outstanding as of the April 15, 2025 record date.
• Stockholders re-elected two Class II directors to serve until the 2028 Annual Meeting: Dr. Anish Bhatnagar and William Harris.
• Dr. Anish Bhatnagar received 42,591,113 votes For, representing 92.3% of voted shares.
• William Harris received 32,331,183 votes For, representing 70.0% of voted shares.
• The appointment of CBIZ CPAs P.C. as the company's independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified with 47,253,371 votes For.

Sentiment

Score: 7

Explanation: The successful completion of the annual meeting with high shareholder participation and the approval of all proposals, including director re-elections and auditor ratification, indicates stable corporate governance. The higher 'withheld' votes for one director are a minor point but do not negate the overall positive outcome of the meeting.

Positives

• High stockholder participation with approximately 94.7% of outstanding shares represented at the meeting, indicating strong engagement.
• Both proposed Class II directors, Dr. Anish Bhatnagar and William Harris, were successfully re-elected.
• The appointment of CBIZ CPAs P.C. as the independent registered public accounting firm was overwhelmingly ratified.

Negatives

• William Harris received a notable percentage of 'Votes Withheld' (13,825,341 votes, representing 30.0% of voted shares), which is significantly higher than Dr. Anish Bhatnagar's 3,565,411 votes withheld (7.7%). While still elected, this indicates a segment of shareholders expressing dissent or abstention regarding his re-election.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of annual meeting results, common across all publicly traded companies. It does not provide specific industry-related insights or trends beyond standard corporate governance practices.

Corporate Governance

Stakeholder Impact

• Shareholders: Directly impacted by the election of directors who represent their interests and the ratification of the auditor, ensuring financial oversight. The high quorum indicates strong shareholder engagement.

Next Steps

• The re-elected Class II directors will serve until the 2028 Annual Meeting of Stockholders.
• CBIZ CPAs P.C. will serve as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

Key Dates

Recommendation

Keywords

Soleno Therapeutics, SLNO, 8-K, Annual Meeting, Stockholders, Director Election, Auditor Ratification, Corporate Governance, Proxy Vote, NASDAQ